Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function
Brain metastasis (BM) is a major cause of suffering and health costs in cancer patients. Whole-brain radiation therapy (WBRT) offers tumor shrinking and palliation in many cases, but it has been speculated that these benefits may be outweighed by adverse effects on neurocognitive function (NCF). Two...
Saved in:
Published in | Journal of clinical oncology Vol. 25; no. 10; pp. 1260 - 1266 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Baltimore, MD
American Society of Clinical Oncology
01.04.2007
Lippincott Williams & Wilkins |
Subjects | |
Online Access | Get full text |
ISSN | 0732-183X 1527-7755 1527-7755 |
DOI | 10.1200/JCO.2006.09.2536 |
Cover
Abstract | Brain metastasis (BM) is a major cause of suffering and health costs in cancer patients. Whole-brain radiation therapy (WBRT) offers tumor shrinking and palliation in many cases, but it has been speculated that these benefits may be outweighed by adverse effects on neurocognitive function (NCF).
Two hundred eight BM patients from the WBRT arm of phase III trial PCI-P120-9801 evaluating motexafin gadolinium were analyzed. NCF, assessed by tests of memory, executive function, and fine motor coordination, was correlated to magnetic resonance imaging-measured BM volume. NCF and survival were compared in 135 patients assessable at 2 months with tumor shrinkage below (poor responders) and above (good responders) the population median (45%). Mean NCF scores and BM volume at 4 and 15 months were compared.
Good responders experienced a significantly improved survival (unidirectional P = .03). For all tests, the median time to NCF deterioration was longer in good compared with poor responders, with statistical significance seen for Trailmaking B (executive function), and two Pegboard tests (fine motor). In long-term survivors, tumor shrinkage significantly correlated with preservation of executive function and fine motor coordination (r = 0.68 to 0.88). During the early follow-up period, the population mean NCF scores were dominated by patients with progressive disease. A small subset of 15-month survivors had stable or improving scores, and greater mean BM reduction.
WBRT-induced tumor shrinkage correlates with better survival and NCF preservation. NCF is stable or improved in long-term survivors. Tumor progression adversely affects NCF more than WBRT does, thus making enhancement of radiation response a worthwhile aim in this patient population. |
---|---|
AbstractList | Brain metastasis (BM) is a major cause of suffering and health costs in cancer patients. Whole-brain radiation therapy (WBRT) offers tumor shrinking and palliation in many cases, but it has been speculated that these benefits may be outweighed by adverse effects on neurocognitive function (NCF).
Two hundred eight BM patients from the WBRT arm of phase III trial PCI-P120-9801 evaluating motexafin gadolinium were analyzed. NCF, assessed by tests of memory, executive function, and fine motor coordination, was correlated to magnetic resonance imaging-measured BM volume. NCF and survival were compared in 135 patients assessable at 2 months with tumor shrinkage below (poor responders) and above (good responders) the population median (45%). Mean NCF scores and BM volume at 4 and 15 months were compared.
Good responders experienced a significantly improved survival (unidirectional P = .03). For all tests, the median time to NCF deterioration was longer in good compared with poor responders, with statistical significance seen for Trailmaking B (executive function), and two Pegboard tests (fine motor). In long-term survivors, tumor shrinkage significantly correlated with preservation of executive function and fine motor coordination (r = 0.68 to 0.88). During the early follow-up period, the population mean NCF scores were dominated by patients with progressive disease. A small subset of 15-month survivors had stable or improving scores, and greater mean BM reduction.
WBRT-induced tumor shrinkage correlates with better survival and NCF preservation. NCF is stable or improved in long-term survivors. Tumor progression adversely affects NCF more than WBRT does, thus making enhancement of radiation response a worthwhile aim in this patient population. Brain metastasis (BM) is a major cause of suffering and health costs in cancer patients. Whole-brain radiation therapy (WBRT) offers tumor shrinking and palliation in many cases, but it has been speculated that these benefits may be outweighed by adverse effects on neurocognitive function (NCF).PURPOSEBrain metastasis (BM) is a major cause of suffering and health costs in cancer patients. Whole-brain radiation therapy (WBRT) offers tumor shrinking and palliation in many cases, but it has been speculated that these benefits may be outweighed by adverse effects on neurocognitive function (NCF).Two hundred eight BM patients from the WBRT arm of phase III trial PCI-P120-9801 evaluating motexafin gadolinium were analyzed. NCF, assessed by tests of memory, executive function, and fine motor coordination, was correlated to magnetic resonance imaging-measured BM volume. NCF and survival were compared in 135 patients assessable at 2 months with tumor shrinkage below (poor responders) and above (good responders) the population median (45%). Mean NCF scores and BM volume at 4 and 15 months were compared.PATIENTS AND METHODSTwo hundred eight BM patients from the WBRT arm of phase III trial PCI-P120-9801 evaluating motexafin gadolinium were analyzed. NCF, assessed by tests of memory, executive function, and fine motor coordination, was correlated to magnetic resonance imaging-measured BM volume. NCF and survival were compared in 135 patients assessable at 2 months with tumor shrinkage below (poor responders) and above (good responders) the population median (45%). Mean NCF scores and BM volume at 4 and 15 months were compared.Good responders experienced a significantly improved survival (unidirectional P = .03). For all tests, the median time to NCF deterioration was longer in good compared with poor responders, with statistical significance seen for Trailmaking B (executive function), and two Pegboard tests (fine motor). In long-term survivors, tumor shrinkage significantly correlated with preservation of executive function and fine motor coordination (r = 0.68 to 0.88). During the early follow-up period, the population mean NCF scores were dominated by patients with progressive disease. A small subset of 15-month survivors had stable or improving scores, and greater mean BM reduction.RESULTSGood responders experienced a significantly improved survival (unidirectional P = .03). For all tests, the median time to NCF deterioration was longer in good compared with poor responders, with statistical significance seen for Trailmaking B (executive function), and two Pegboard tests (fine motor). In long-term survivors, tumor shrinkage significantly correlated with preservation of executive function and fine motor coordination (r = 0.68 to 0.88). During the early follow-up period, the population mean NCF scores were dominated by patients with progressive disease. A small subset of 15-month survivors had stable or improving scores, and greater mean BM reduction.WBRT-induced tumor shrinkage correlates with better survival and NCF preservation. NCF is stable or improved in long-term survivors. Tumor progression adversely affects NCF more than WBRT does, thus making enhancement of radiation response a worthwhile aim in this patient population.CONCLUSIONWBRT-induced tumor shrinkage correlates with better survival and NCF preservation. NCF is stable or improved in long-term survivors. Tumor progression adversely affects NCF more than WBRT does, thus making enhancement of radiation response a worthwhile aim in this patient population. |
Author | Markus Renschler Jing Li Soren M. Bentzen Minesh P. Mehta |
Author_xml | – sequence: 1 givenname: Jing surname: Li fullname: Li, Jing organization: From the Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI; and Oncology Clinical Development, Pharmacyclics, Sunnyvale, CA – sequence: 2 givenname: Soren M. surname: Bentzen fullname: Bentzen, Soren M. organization: From the Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI; and Oncology Clinical Development, Pharmacyclics, Sunnyvale, CA – sequence: 3 givenname: Markus surname: Renschler fullname: Renschler, Markus organization: From the Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI; and Oncology Clinical Development, Pharmacyclics, Sunnyvale, CA – sequence: 4 givenname: Minesh P. surname: Mehta fullname: Mehta, Minesh P. organization: From the Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, Madison, WI; and Oncology Clinical Development, Pharmacyclics, Sunnyvale, CA |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18683364$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17401015$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kd1rFDEUxYNU7Lb67pPkRX2aNR-T-XhsF1sr1UKt1LeQZm52UrKTNcls6aP_uRlnVRCEwA3c37m5OecIHQx-AIReUrKkjJB3H1dXy1yrJWmXTPDqCVpQweqiroU4QAtSc1bQhn87REcx3hNCy4aLZ-iQ1iWhhIoF-nEN6wAxWj_gE5Mg4NveOyhOg7IDvladVWnq3fQQ1PYRGx_w3PsEScV8IOKVDwGcSvl6a1OPv4xhZ3fKYTV0-GKzDX4HHf4MY_Darweb7A7w2TjoafRz9NQoF-HFvh6jr2fvb1Yfisur84vVyWWh866pMIyVhNXEiJYAM1DWlEPXakNbYVhLTGO0INwYCuVdo1RLSXakbhlvtOl4yY_Rm3luXuf7CDHJjY0anFMD-DHKmnBWtaLJ4Ks9ON5toJPbYDcqPMrfpmXg9R5QUStnghq0jX-5pmo4r6YXq5nTwccYwEht0y87U3bQSUrklKLMKcopRUlaOaWYheQf4Z_Z_5e8nSW9XfcPNoCMG-Vc_gKT99ozMUsrwn8Cw6esvQ |
CitedBy_id | crossref_primary_10_1016_j_meddos_2021_02_007 crossref_primary_10_1007_s11060_011_0654_x crossref_primary_10_3390_curroncol29040210 crossref_primary_10_7243_2054_1945_2_3 crossref_primary_10_1016_j_radonc_2014_01_012 crossref_primary_10_2217_cns_12_33 crossref_primary_10_1016_j_radonc_2016_05_030 crossref_primary_10_1155_2010_198208 crossref_primary_10_1016_S1470_2045_09_70387_0 crossref_primary_10_1007_s12254_008_0031_4 crossref_primary_10_1016_j_cct_2015_12_013 crossref_primary_10_1016_j_ijrobp_2007_04_024 crossref_primary_10_3390_cancers14112736 crossref_primary_10_1016_j_currproblcancer_2015_03_001 crossref_primary_10_1016_j_surneu_2009_02_011 crossref_primary_10_1002_cncr_28307 crossref_primary_10_1016_j_heliyon_2022_e10109 crossref_primary_10_1097_MJT_0000000000000106 crossref_primary_10_1100_2012_721598 crossref_primary_10_1016_j_adro_2017_08_013 crossref_primary_10_1007_s11060_015_2009_5 crossref_primary_10_1016_j_hoc_2012_04_007 crossref_primary_10_1186_1748_717X_8_156 crossref_primary_10_1176_foc_7_3_foc317 crossref_primary_10_1177_11795549221079185 crossref_primary_10_1371_journal_pone_0143208 crossref_primary_10_3390_jpm11060532 crossref_primary_10_5301_tj_5000657 crossref_primary_10_1227_NEU_0000000000000354 crossref_primary_10_1016_j_ijrobp_2009_03_016 crossref_primary_10_1016_j_nurt_2009_04_012 crossref_primary_10_1120_jacmp_v14i3_4205 crossref_primary_10_1634_theoncologist_2018_0544 crossref_primary_10_1007_s00115_017_0423_y crossref_primary_10_1007_s00761_022_01230_8 crossref_primary_10_1016_S0140_6736_16_31391_5 crossref_primary_10_3390_neurosci5040034 crossref_primary_10_1016_j_canrad_2013_07_139 crossref_primary_10_1016_S1470_2045_12_70518_1 crossref_primary_10_1016_j_radonc_2014_12_011 crossref_primary_10_1016_j_ctro_2021_11_008 crossref_primary_10_1002_cam4_2696 crossref_primary_10_3390_cancers15123193 crossref_primary_10_1186_1748_717X_9_218 crossref_primary_10_1002_cam4_4192 crossref_primary_10_1007_s11060_007_9515_z crossref_primary_10_1016_j_ijrobp_2011_09_032 crossref_primary_10_1371_journal_pone_0126222 crossref_primary_10_1016_j_ijrobp_2009_08_025 crossref_primary_10_1200_GO_23_00143 crossref_primary_10_3238_arztebl_m2021_0024 crossref_primary_10_1016_j_clineuro_2011_10_013 crossref_primary_10_4143_crt_2018_206 crossref_primary_10_1200_JCO_21_00639 crossref_primary_10_18632_oncotarget_19333 crossref_primary_10_1007_s00066_011_2260_4 crossref_primary_10_1016_S1470_2045_16_30065_1 crossref_primary_10_1186_1471_2407_11_395 crossref_primary_10_1016_S1470_2045_14_70151_2 crossref_primary_10_1080_14737140_2019_1582336 crossref_primary_10_1200_JCO_2015_60_9297 crossref_primary_10_3389_fonc_2020_572644 crossref_primary_10_3389_fonc_2021_631422 crossref_primary_10_1007_s11060_014_1550_y crossref_primary_10_1007_s10555_008_9132_0 crossref_primary_10_1002_cncr_28237 crossref_primary_10_1002_cncr_31649 crossref_primary_10_1007_s00066_022_01916_3 crossref_primary_10_1111_cas_13079 crossref_primary_10_3390_cancers16234122 crossref_primary_10_1155_2013_568597 crossref_primary_10_1684_bdc_2012_1613 crossref_primary_10_3390_ijms21228534 crossref_primary_10_1016_j_radonc_2016_10_005 crossref_primary_10_1586_era_11_165 crossref_primary_10_3171_2016_7_GKS161499 crossref_primary_10_1007_s11060_009_9833_4 crossref_primary_10_1007_s11864_013_0258_0 crossref_primary_10_1002_cam4_1784 crossref_primary_10_1007_s11060_019_03292_y crossref_primary_10_3390_cancers2042100 crossref_primary_10_3171_2014_6_GKS14708 crossref_primary_10_2217_cns_14_22 crossref_primary_10_3389_fneur_2018_00758 crossref_primary_10_1093_annonc_mdy554 crossref_primary_10_1016_j_ijrobp_2011_03_044 crossref_primary_10_1200_JCO_2010_33_3294 crossref_primary_10_1007_s11060_009_0051_x crossref_primary_10_1200_JCO_2007_12_8686 crossref_primary_10_1016_j_clon_2015_06_005 crossref_primary_10_1007_s00259_012_2150_8 crossref_primary_10_1016_j_critrevonc_2022_103600 crossref_primary_10_37549_ARO1065 crossref_primary_10_1016_j_ijrobp_2014_08_004 crossref_primary_10_1186_s12885_023_11286_3 crossref_primary_10_1007_s00066_009_1904_0 crossref_primary_10_1016_j_prro_2015_08_001 crossref_primary_10_1016_S1470_2045_17_30692_7 crossref_primary_10_1016_j_adro_2017_05_008 crossref_primary_10_1016_j_clon_2017_05_001 crossref_primary_10_1016_j_ijrobp_2013_07_037 crossref_primary_10_1016_j_adro_2016_03_004 crossref_primary_10_1016_j_ejmp_2017_09_129 crossref_primary_10_1007_s11910_014_0518_9 crossref_primary_10_1002_acm2_12277 crossref_primary_10_1007_s00520_008_0431_3 crossref_primary_10_1016_j_ijrobp_2013_02_033 crossref_primary_10_1016_j_ijrobp_2009_02_091 crossref_primary_10_3892_br_2013_151 crossref_primary_10_1016_j_ijrobp_2014_03_001 crossref_primary_10_1093_neuonc_nox195 crossref_primary_10_3389_fonc_2019_00206 crossref_primary_10_3390_brainsci14121295 crossref_primary_10_1016_j_meddos_2017_06_007 crossref_primary_10_4103_jcrt_jcrt_1724_22 crossref_primary_10_1016_j_rpor_2013_03_002 crossref_primary_10_1186_1748_717X_7_77 crossref_primary_10_1016_j_ijrobp_2007_09_015 crossref_primary_10_1200_JCO_20_01823 crossref_primary_10_1002_pro6_1214 crossref_primary_10_1186_s13014_015_0553_y crossref_primary_10_1007_s00761_011_2014_z crossref_primary_10_3390_brainsci7100122 crossref_primary_10_1097_01_JTO_0000282983_03866_9d crossref_primary_10_1016_j_ijrobp_2010_10_044 crossref_primary_10_1177_1559325820938279 crossref_primary_10_1016_j_ijrobp_2012_09_025 crossref_primary_10_1016_j_canrad_2012_03_010 crossref_primary_10_1016_j_nec_2010_08_010 crossref_primary_10_1016_j_ijrobp_2017_07_033 crossref_primary_10_1056_NEJMct0806951 crossref_primary_10_1007_s11839_016_0563_5 crossref_primary_10_1002_14651858_CD009454_pub2 crossref_primary_10_1016_S1470_2045_13_70308_5 crossref_primary_10_1038_s41571_019_0320_3 crossref_primary_10_1016_j_ijrobp_2012_02_036 crossref_primary_10_1016_j_cllc_2014_06_008 crossref_primary_10_1016_j_nec_2010_08_001 crossref_primary_10_1186_1748_717X_3_26 crossref_primary_10_1016_j_prro_2013_09_006 crossref_primary_10_1186_1471_2407_12_283 crossref_primary_10_1016_S1470_2045_13_70311_5 crossref_primary_10_1586_era_12_34 crossref_primary_10_1093_neuonc_now241 crossref_primary_10_1002_acm2_13837 crossref_primary_10_1016_j_semradonc_2009_08_003 crossref_primary_10_1016_j_ijrobp_2007_11_047 crossref_primary_10_1016_S1470_2045_17_30441_2 crossref_primary_10_2217_lmt_14_44 crossref_primary_10_1007_s11060_011_0590_9 crossref_primary_10_1259_bjr_20170099 crossref_primary_10_3390_ijms15058138 crossref_primary_10_1200_JCO_2017_77_5817 crossref_primary_10_15406_jlprr_2022_09_00286 crossref_primary_10_1007_s11060_009_9960_y crossref_primary_10_1007_s11940_010_0074_9 crossref_primary_10_1177_1533034614566993 crossref_primary_10_1016_j_jocn_2012_09_026 crossref_primary_10_1177_17588359231175438 crossref_primary_10_1177_1533033821997819 crossref_primary_10_1177_1533034615590934 crossref_primary_10_1186_s40164_015_0028_8 crossref_primary_10_18632_oncotarget_19054 crossref_primary_10_1016_j_semradonc_2015_02_008 crossref_primary_10_2217_cns_14_51 crossref_primary_10_1007_s11033_022_08211_5 crossref_primary_10_1007_s11912_011_0205_9 crossref_primary_10_1200_JCO_2015_60_9503 crossref_primary_10_1007_s11912_009_0072_9 crossref_primary_10_1097_CCO_0b013e32831186fe crossref_primary_10_1007_s12325_009_0047_0 crossref_primary_10_1016_j_ijrobp_2007_05_038 crossref_primary_10_1080_09553002_2019_1554920 crossref_primary_10_1200_JCO_2007_12_4610 crossref_primary_10_1177_1758835920936117 crossref_primary_10_1016_j_ijrobp_2007_09_059 crossref_primary_10_1016_j_canrad_2016_02_007 crossref_primary_10_1200_JCO_2010_29_6053 crossref_primary_10_1007_s11060_015_1971_2 crossref_primary_10_37549_ARO1119 crossref_primary_10_1016_j_currproblcancer_2010_04_003 crossref_primary_10_1007_s12254_021_00710_8 crossref_primary_10_1016_j_ijrobp_2008_02_054 crossref_primary_10_1016_j_radonc_2010_09_013 crossref_primary_10_1002_cncr_23069 crossref_primary_10_5812_rro_95524 crossref_primary_10_1007_s11654_007_0020_9 crossref_primary_10_1158_2326_6066_CIR_13_0007 crossref_primary_10_1227_01_neu_0000316899_55501_8b crossref_primary_10_1007_s11864_016_0423_3 crossref_primary_10_3389_fpsyg_2020_573919 crossref_primary_10_1016_j_radonc_2011_08_041 crossref_primary_10_1016_j_cllc_2018_05_003 crossref_primary_10_1007_s00280_011_1775_9 crossref_primary_10_1007_s10555_016_9619_z crossref_primary_10_1016_j_breast_2016_10_006 crossref_primary_10_1007_s12094_022_02927_3 crossref_primary_10_1159_000518848 crossref_primary_10_1093_annonc_mdy275 crossref_primary_10_1016_j_canrad_2013_06_042 crossref_primary_10_1001_jama_2016_9839 crossref_primary_10_1684_bdc_2012_1682 crossref_primary_10_3389_fonc_2024_1395313 crossref_primary_10_3389_fonc_2018_00161 crossref_primary_10_1007_s00330_022_08887_0 crossref_primary_10_1200_JCO_2014_58_4367 crossref_primary_10_1016_j_rpor_2012_08_003 crossref_primary_10_1186_s12885_020_6559_3 crossref_primary_10_1007_s11060_012_0821_8 crossref_primary_10_1007_s00432_023_05538_9 crossref_primary_10_1007_s11060_018_2958_6 crossref_primary_10_1097_MD_0000000000023592 crossref_primary_10_2174_1573394715666181129105542 crossref_primary_10_3109_09553002_2014_925607 crossref_primary_10_1016_j_jtho_2016_05_013 crossref_primary_10_1136_bcr_2023_257988 crossref_primary_10_1186_s40644_021_00410_w crossref_primary_10_1097_WCO_0b013e32833f8cb5 crossref_primary_10_1007_s11060_012_0976_3 crossref_primary_10_1016_j_clon_2012_08_004 crossref_primary_10_1200_JCO_2015_60_9305 crossref_primary_10_1016_j_breast_2019_10_007 crossref_primary_10_1016_j_ijrobp_2023_03_044 crossref_primary_10_1002_cncr_32787 crossref_primary_10_3857_roj_2015_33_3_207 crossref_primary_10_1016_j_ehmc_2016_02_003 crossref_primary_10_23736_S0390_5616_20_04952_8 crossref_primary_10_1586_ern_10_30 |
Cites_doi | 10.1200/JCO.2005.04.6185 10.1097/01.COC.0000020585.85901.7C 10.1016/S0360-3016(01)01676-5 10.1200/JCO.2002.07.500 10.1038/nm749 10.1200/JCO.2005.04.6086 10.1200/JCO.2003.12.122 10.1200/JCO.2004.05.128 10.1212/WNL.39.6.789 10.3109/07853899809005858 10.1097/00019052-200304000-00002 10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8 |
ContentType | Journal Article |
Copyright | 2007 INIST-CNRS |
Copyright_xml | – notice: 2007 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1200/JCO.2006.09.2536 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 1266 |
ExternalDocumentID | 17401015 18683364 10_1200_JCO_2006_09_2536 jco25_10_1260 |
Genre | Clinical Trial, Phase III Multicenter Study Journal Article |
GroupedDBID | - 0R 2WC 34G 39C 3O- 4.4 53G 55 5GY 5RE 8F7 8WZ A6W AAPEM AARDX AAWTL AAYEP ABFLS ABOCM ACDCL ACGFS ADBBV ADBIT ADKWQ AENEX AFFNX ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL CS3 DIK EBS EJD F5P FD8 FH7 GJ GX1 H13 HZ IH2 K-O KQ8 L7B LSO N9A O9- OK1 OVD OWW P2P RHI RUC SJN SV3 TWZ UDS VH1 WH7 X7M YCJ ZA5 --- .55 .GJ 0R~ 18M AAYOK AAYXX ABBLC ABJNI ACGFO ACGUR AEGXH AI. AIAGR C45 CITATION F9R FBNNL HZ~ MJL N4W QTD R1G RLZ TEORI TR2 VVN YFH YQY 08G 08P 29K 5VS AAKAS AAQOH AAQQT ADZCM ASPBG AVWKF AZFZN BYPQX D-I EX3 FEDTE HVGLF IPNFZ IQODW J5H NTWIH RIG UHU WOQ WOW ZGI CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c401t-f2240270f590e2fe4713ed9cf195f290f8fc503ff1e4b8aa91025379238cfd343 |
ISSN | 0732-183X 1527-7755 |
IngestDate | Tue Aug 05 10:00:45 EDT 2025 Thu Apr 03 07:02:44 EDT 2025 Mon Jul 21 09:11:37 EDT 2025 Tue Jul 01 01:10:59 EDT 2025 Thu Apr 24 23:11:45 EDT 2025 Tue Jan 05 20:17:21 EST 2021 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 10 |
Keywords | Nervous system diseases Cancerology Treatment Brain cancer Central nervous system disease Regression Malignant tumor Radiotherapy Cerebral metastasis Survival Cerebral disorder |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c401t-f2240270f590e2fe4713ed9cf195f290f8fc503ff1e4b8aa91025379238cfd343 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2006.09.2536 |
PMID | 17401015 |
PQID | 70326958 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_70326958 pubmed_primary_17401015 pascalfrancis_primary_18683364 crossref_citationtrail_10_1200_JCO_2006_09_2536 crossref_primary_10_1200_JCO_2006_09_2536 highwire_smallpub2_jco25_10_1260 |
ProviderPackageCode | RHI CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2007-04-01 |
PublicationDateYYYYMMDD | 2007-04-01 |
PublicationDate_xml | – month: 04 year: 2007 text: 2007-04-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Baltimore, MD |
PublicationPlace_xml | – name: Baltimore, MD – name: United States |
PublicationTitle | Journal of clinical oncology |
PublicationTitleAlternate | J Clin Oncol |
PublicationYear | 2007 |
Publisher | American Society of Clinical Oncology Lippincott Williams & Wilkins |
Publisher_xml | – name: American Society of Clinical Oncology – name: Lippincott Williams & Wilkins |
References | R2 R3 R4 R5 R6 R7 R8 R9 R10 R12 R11 R14 R13 R15 R1 17761992 - J Clin Oncol. 2007 Sep 1;25(25):4023; author reply 4024-5 |
References_xml | – ident: R12 – ident: R15 doi: 10.1200/JCO.2005.04.6185 – ident: R5 doi: 10.1097/01.COC.0000020585.85901.7C – ident: R9 doi: 10.1016/S0360-3016(01)01676-5 – ident: R11 doi: 10.1200/JCO.2002.07.500 – ident: R14 doi: 10.1038/nm749 – ident: R10 doi: 10.1200/JCO.2005.04.6086 – ident: R7 doi: 10.1200/JCO.2003.12.122 – ident: R6 doi: 10.1200/JCO.2004.05.128 – ident: R8 doi: 10.1212/WNL.39.6.789 – ident: R3 doi: 10.3109/07853899809005858 – ident: R13 doi: 10.1097/00019052-200304000-00002 – ident: R1 – ident: R4 – ident: R2 doi: 10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8 – reference: 17761992 - J Clin Oncol. 2007 Sep 1;25(25):4023; author reply 4024-5 |
SSID | ssj0014835 |
Score | 2.3945823 |
Snippet | Brain metastasis (BM) is a major cause of suffering and health costs in cancer patients. Whole-brain radiation therapy (WBRT) offers tumor shrinking and... |
SourceID | proquest pubmed pascalfrancis crossref highwire |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1260 |
SubjectTerms | Adult Biological and medical sciences Brain - physiopathology Brain Neoplasms - mortality Brain Neoplasms - psychology Brain Neoplasms - radiotherapy Brain Neoplasms - secondary Cognition Cranial Irradiation Humans Medical sciences Neurology Prospective Studies Quality of Life Tumors Tumors of the nervous system. Phacomatoses |
Title | Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function |
URI | http://jco.ascopubs.org/content/25/10/1260.abstract https://www.ncbi.nlm.nih.gov/pubmed/17401015 https://www.proquest.com/docview/70326958 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1527-7755 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014835 issn: 0732-183X databaseCode: KQ8 dateStart: 19990101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1527-7755 dateEnd: 20240930 omitProxy: true ssIdentifier: ssj0014835 issn: 0732-183X databaseCode: DIK dateStart: 20040101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1527-7755 dateEnd: 20240930 omitProxy: true ssIdentifier: ssj0014835 issn: 0732-183X databaseCode: GX1 dateStart: 20040101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBAvCMZX-Rh-QJNQly5xEid53ArTGCqtpk7sLXIymwp16bSmSN0bfyr_CXexEzcb3y9RlQ_H8f16d7bvfkfIa3ABYN4QBk4OvixMUKLAEUIFDujFkIM5TFi1Djn8yA9PgqPT8LTT-b4WtbQss35-9dO8kv-RKpwDuWKW7D9ItmkUTsBvkC8cQcJw_CsZH8vPOoy16O1Vtb4_YbVbZx_LPvSOkXWgku5EMwdUEYX62lCWAtzChcSKnZdVPovESNhyCpoElMdXwyCglxzAJ604PGyo0QFYw0aiN13bJt1yXuStZfsjnVPVLOvMMY182O_tg-m7sklpmEC0xASWAubeMxs_PMQY_Wlv3IcPmJaitWIRrQW62CQB1F4mLhXjTup-jdb7pdVg5DMHFM-ptlhGTbMI5gWa4LfW4zqBusaru6aVPaZrFtwwF0xXwh6MzK5U0meh5mNZQ8_FeQUfD2sXujr3tM3bfc2eNlGOX_I5C1OcZcH7b5HbLOIci2y8ff-h2egKYl0Dtv5Is5MO3dm93i3ktzV9aDtRNbE1xvWKBYyi0jVZfj1pqpynyX1yz0CD7mkIPyAdWWySO0MT17FJtseaQX21Qyc2IXCxQ7fp2HKrrx6SbxbytII8XYM8bSBvWllRgDzV1yzkqYU8RcjTGvIUIE9ryNM25GkN-Ufk5ODdZHDomCoiTg6DVToKnVYWuSpMXMmUBG_Ml2dJrrwkVCxxVazy0PWV8mSQxUKA_wyjjbSaca7O_MB_TDaKeSGfEsqRzTDiwsukF4SZK2LuR0omIkx4kvGsS3ZrsaS5odjHSi8zDQLcNx6MsPArT90kRZl2yZvmiQtNL_Obe2kt6XRxLmYzkChLWyDrkq0WAmybMY99nwdd8qqGRAp2BDcHRSHny0UKlp_xJIy75IlGin3WgO7Zn9__nNy1f_gXZKO8XMqX4LSX2VYF-x98CO1v |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Regression+After+Whole-Brain+Radiation+Therapy+for+Brain+Metastases+Correlates+With+Survival+and+Improved+Neurocognitive+Function&rft.jtitle=Journal+of+clinical+oncology&rft.au=Jing+Li&rft.au=Soren+M.+Bentzen&rft.au=Markus+Renschler&rft.au=Minesh+P.+Mehta&rft.date=2007-04-01&rft.pub=American+Society+of+Clinical+Oncology&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=25&rft.issue=10&rft.spage=1260&rft_id=info:doi/10.1200%2FJCO.2006.09.2536&rft_id=info%3Apmid%2F17401015&rft.externalDBID=n%2Fa&rft.externalDocID=jco25_10_1260 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |